This article aims to critically compare the available evidence regarding the efficacy, safety, and clinical outcomes associated with trastuzumab plus gemcitabine versus lapatinib plus capecitabine in third-line settings following T-DM1 failure in patients with metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.